Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Oct;60(4):627–629. doi: 10.1038/bjc.1989.327

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

D Pectasides 1, H Yianniotis 1, N Alevizakos 1, D Bafaloukos 1, V Barbounis 1, J Varthalitis 1, M Dimitriadis 1, A Athanassiou 1
PMCID: PMC2247122  PMID: 2803936

Abstract

Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.

Full text

PDF
627

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carey R. W., Anderson J. R., Green M., Ellison R. R., Nathanson L., Kennedy B. J. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B. Cancer Treat Rep. 1986 Mar;70(3):329–331. [PubMed] [Google Scholar]
  2. Chary K. K., Higby D. J., Henderson E. S., Swinerton K. D. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep. 1977 May-Jun;61(3):367–370. [PubMed] [Google Scholar]
  3. Comis R. L. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep. 1976 Feb;60(2):165–176. [PubMed] [Google Scholar]
  4. Costanzi J. J. DTIC (NSC-45388) studies in the southwest oncology group. Cancer Treat Rep. 1976 Feb;60(2):189–192. [PubMed] [Google Scholar]
  5. Creagan E. T., Ahmann D. L., Schutt A. J., Green S. J. Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma. Cancer Treat Rep. 1982 Mar;66(3):567–569. [PubMed] [Google Scholar]
  6. Einhorn L. H., Burgess M. A., Vallejos C., Bodey G. P., Sr, Gutterman J., Mavligit G., Hersh E. M., Luce J. K., Frei E., 3rd, Freireich E. J. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974 Aug;34(8):1995–2004. [PubMed] [Google Scholar]
  7. Friedman M. A., Kaufman D. A., Williams J. E., Resser K. J., Rosenbaum E. H., Cohen R. J., Glassberg A. B., Blume M. R., Gershow J., Chan E. Y. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study. Cancer Treat Rep. 1979 Mar;63(3):493–495. [PubMed] [Google Scholar]
  8. Hill G. J., 2nd, Krementz E. T., Hill H. Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984 Mar 15;53(6):1299–1305. doi: 10.1002/1097-0142(19840315)53:6<1299::aid-cncr2820530613>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  9. Karakousis C. P., Getaz E. P., Bjornsson S., Henderson E. S., Irequi M., Martinez L., Ospina J., Cavins J., Preisler H., Holyoke E. cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2009–2010. [PubMed] [Google Scholar]
  10. Luikart S. D., Kennealey G. T., Kirkwood J. M. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984 Mar;2(3):164–168. doi: 10.1200/JCO.1984.2.3.164. [DOI] [PubMed] [Google Scholar]
  11. Nathanson L., Kaufman S. D., Carey R. W. Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer. 1981 Sep 15;48(6):1290–1294. doi: 10.1002/1097-0142(19810915)48:6<1290::aid-cncr2820480605>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  12. Oratz R., Speyer J. L., Green M., Blum R., Wernz J. C., Muggia F. M. Treatment of metastatic malignant melanoma with dacarbazine and cisplatin. Cancer Treat Rep. 1987 Sep;71(9):877–878. [PubMed] [Google Scholar]
  13. Pritchard K. I., Quirt I. C., Cowan D. H., Osoba D., Kutas G. J. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1123–1126. [PubMed] [Google Scholar]
  14. York R. M., Lawson D. H., McKay J. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer. 1983 Dec 15;52(12):2220–2222. doi: 10.1002/1097-0142(19831215)52:12<2220::aid-cncr2820521208>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES